These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36214611)

  • 1. COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.
    Aryanian Z; Balighi K; Afshar ZM; Zamanian MH; Razavi Z; Hatami P
    J Cosmet Dermatol; 2022 Dec; 21(12):6568-6573. PubMed ID: 36214611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.
    Aryanian Z; Balighi K; Hatami P; Goodarzi A; Mohandesi NA; Afshar ZM
    Dermatol Ther; 2022 May; 35(5):e15430. PubMed ID: 35261123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Various aspects of the relationship between vitiligo and the COVID-19 pandemic or SARS-CoV-2 vaccines: Clinical pearls for dermatologists.
    Aryanian Z; Balighi K; Hatami P; Goodarzi A; Janbakhsh A; Afshar ZM
    J Cosmet Dermatol; 2023 Apr; 22(4):1152-1156. PubMed ID: 36762373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.
    Gresham LM; Marzario B; Dutz J; Kirchhof MG
    J Am Acad Dermatol; 2021 Jun; 84(6):1652-1666. PubMed ID: 33482251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.
    Wang C; Rademaker M; Tate B; Baker C; Foley P
    Australas J Dermatol; 2021 May; 62(2):151-156. PubMed ID: 33786833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [COVID-19 Vaccines for Patients with Neuroimmunological Diseases].
    Ogawa R; Nakashima I
    Brain Nerve; 2022 Jul; 74(7):899-904. PubMed ID: 35860938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Int; 2022 Jan; 64(1):e15331. PubMed ID: 36331234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
    Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
    Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the safety and efficacy of current COVID-19 vaccines.
    Huang Z; Su Y; Zhang T; Xia N
    Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.
    Syversen SW; Jyssum I; Tveter AT; Tran TT; Sexton J; Provan SA; Mjaaland S; Warren DJ; Kvien TK; Grødeland G; Nissen-Meyer LSH; Ricanek P; Chopra A; Andersson AM; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Lund-Johansen F; Jørgensen KK; Goll GL
    Arthritis Rheumatol; 2022 Aug; 74(8):1321-1332. PubMed ID: 35507355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.
    Wasserbauer M; Hlava S; Trojanek M; Stovicek J; Milota T; Drabek J; Koptová P; Cupkova A; Pichlerová D; Kucerova B; Coufal S; Keil R
    PLoS One; 2022; 17(9):e0273612. PubMed ID: 36054100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.